Pharma Focus Asia

Merck Develops First-in-Class WINREVAIR™ Treatment for Pulmonary Arterial Hypertension

Merck has developed WINREVAIR™ (sotatercept-csrk), a groundbreaking treatment designed for adults with pulmonary arterial hypertension (PAH). This medication aims to enhance exercise capacity, elevate WHO functional class (FC), and diminish the risk of clinical worsening events.

WINREVAIR marks a significant advancement as the first FDA-approved activin signalling inhibitor therapy for PAH, ushering in a new era of treatment by rebalancing pro- and anti-proliferative signalling crucial for regulating vascular cell proliferation underlying PAH.

Clinical trials have revealed that the addition of WINREVAIR to existing PAH therapies results in notable clinical benefits when compared to standard PAH treatment alone. This approval marks a pivotal moment, providing healthcare providers with a fresh therapeutic avenue that targets a novel PAH treatment pathway.

By modulating vascular proliferation through restoring the equilibrium between pro-proliferative and anti-proliferative signalling, WINREVAIR brings about transformative changes. Preclinical investigations have revealed that WINREVAIR induces cellular changes correlated with thinner vessel walls, a partial reversal of right ventricular remodelling, and enhanced haemodynamics.

PAH is a rare, progressive, and potentially fatal condition characterised by the thickening and narrowing of blood vessels in the lungs, imposing significant strain on the heart.

The U.S. food and drug administration (FDA) has granted WINREVAIR breakthrough status as a biologic for adults afflicted with pulmonary arterial hypertension.


 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024